EHA 2023 | Elotuzumab plus KRd versus KRd for newly diagnosed multiple myeloma: Phase III trial results
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses a recent Phase III study (NCT03948035) comparing a triplet therapy of carfilzomib, lenalidomide and dexamethasone (KRd) to a quadruplet therapy of KRd plus elotuzumab (E-KRd) before and after autologous stem cell transplantation (autoSCT) in patients with newly diagnosed multiple myeloma. In this study, patients receiving E-KRd achieved higher rates of very good partial response (VGPR) or better and improved MRD-negativity, the two co-primary endpoints. Prof. Einsele comments on the success of the addition of a monoclonal antibody to a triplet regimen in improving response quality following induction therapy. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
That was the so-called DSNM-70 study in which, again, a quadruple therapy was compared to a triple therapy and, as already shown for other quadruple combinations, the addition in this case of elotuzumab to KRd – KRd was given as three cycles before stem cell collections, three cycles after stem cell collections and four cycles following transplant. After the induction treatments, so six cycles of either elo-KRd versus six cycles of KRd, there was clearly a higher rate of very good partial remission or better and also a significantly improved MRD-negativity in favor of the quadruple combination...
That was the so-called DSNM-70 study in which, again, a quadruple therapy was compared to a triple therapy and, as already shown for other quadruple combinations, the addition in this case of elotuzumab to KRd – KRd was given as three cycles before stem cell collections, three cycles after stem cell collections and four cycles following transplant. After the induction treatments, so six cycles of either elo-KRd versus six cycles of KRd, there was clearly a higher rate of very good partial remission or better and also a significantly improved MRD-negativity in favor of the quadruple combination. So, I think that we now also have, for the combination elo-KRd, the information that the addition of a monoclonal antibody to a triplet regimen improves at least the response, quality and MRD-negativity following induction therapy.
Read more...
